Experimental studies further show that IGFBP-3 overexpression induces insulin resistance and dyslipidemia, while partial IGF-1 deficiency enhances gluconeogenic and lipogenic gene expression changes reversible with IGF-1 replacement [27]. This evidence concerns the gene IGFBP3 and metabolic syndrome.